Breast Cacner: Lupron 7.5mg monthly versus 22.5 mg every 3 motnhs – pro
Adjuvant therapy of breast cancer with leuprlide Is standard and recommended by NCCN. The FDA approval of 22.5 mg is for prostate cancer and gender change treatment; however; that is simply an artifact of how studies were done and with what doses. Other leuprolide doses are approved for breast cancer. It is, therefore, common practice and generally accepted for 22.5 mg dose to also be used for breast cancer. Kendzierski et al found that Leuprolide acetate depot administered every 3 months is as efficacious and tolerable as a monthly injection in combination with an aromatase inhibitor for premenopausal patients with hormone receptorpositive breast cancer.
Daniel C. Kendzierski et al, Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective, Review. BREAST CANCER VOLUME 18, ISSUE 5, E939-E942, OCTOBER 01, 2018